<a href="https://laohu8.com/S/EPIX">ESSA Pharma Inc.</a> Publishes Shareholder Letter for Fiscal Year 2025
ESSA Pharma Inc. has issued a letter to shareholders regarding a Business Combination Agreement entered into on July 13, 2025. The agreement involves a transaction where XenoTherapeutics, Inc., through its subsidiary Xeno Acquisition Corp., will acquire all issued and outstanding common shares of ESSA Pharma Inc. The company plans to reduce the capital of its common shares and make a concurrent distribution, subject to approval from the Supreme Court of British Columbia. The letter provides information on the potential tax treatment of the proposed distribution and highlights considerations relevant to shareholders' individual circumstances. More detailed tax information will be available in the proxy statement and management information circular filed with the United States Securities and Exchange Commission. The full letter can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-072771), on July 31, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。